Semaglutide GLP-1 is suitable for patients with a BMI of 30+ (obesity) or 27+ (overweight) with a weight-related comorbidity
For example, dual-agent nanoplatforms co-delivering BH3 mimetics with low-dose doxorubicin have been proposed to exploit mitochondrial priming and DNA damage simultaneously, enhancing apoptosis while reducing the dose-dependent cardiotoxicity of doxorubicin
Cell Rep Med 4(11) Dankner R, Murad H, Agay N, Olmer L, Freedman LS (2024) Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes
Lean protein, gentle carbs, cooked produce, then only a small amount of added fat
Spitz and Georgina also talk about who should NOT take GLP-1s and for which patients they simply wont write a prescription